

**05.02.2018**

09:30 - 11:00	The diseases Moderation: P.G. Casali, P. Collini; Milan, IT	Club bar
09:30 - 09:55	The natural history of STS & GIST <u>P.G. Casali</u> , Milan, IT	
09:55 - 10:20	The pathology of STS && <u>A..P. Dei Tos</u> , Treviso, IT	
10:20 - 10:45	The "clinical" genetics of GIST <u>M. Pantaleo</u> , Bologna, IT	
10:45 - 11:00	Discussion	
09:30 - 11:00	Localised GIST: Case discussions Moderation: M. Eriksson <sup>1</sup> , E. Wardelmann <sup>2</sup> ; <sup>1</sup> Lund, SE, <sup>2</sup> Münster, DE	Washington A
09:30 - 11:00	Localised GIST: Case discussions <u>R.S. Benjamin</u> <sup>1</sup> , <u>R.P. DeMatteo</u> <sup>2</sup> , <u>P. Hohenberger</u> <sup>3</sup> , <u>P. Rutkowski</u> <sup>4</sup> , <u>V. Quagliuolo</u> <sup>5</sup> ; <sup>1</sup> Houston, TX/US, <sup>2</sup> New York, NY/US, <sup>3</sup> Mannheim, DE, <sup>4</sup> Warsaw, PL, <sup>5</sup> Rozzano, (MI)/IT	
11:30 - 13:00	Principles of local treatment Moderation: A. Fedenko <sup>1</sup> , V. Quagliuolo <sup>2</sup> ; <sup>1</sup> Moscow, RU, <sup>2</sup> Rozzano, (MI)/IT	Club bar
11:30 - 12:00	Surgical margins in STS & GIST <u>P. Hohenberger</u> , Mannheim, DE	
12:00 - 12:30	Principles of radiation therapy in STS <u>R.L. Haas</u> , Amsterdam, NL	
12:30 - 13:00	Retroperitoneal sarcomas <u>S. Bonvalot</u> , Paris, CEDEX/FR	

- 11:30 - 13:00 Metastatic GIST: Case discussions Washington A  
Moderation: J. Martin Broto<sup>1</sup>, B. Kasper<sup>2</sup>; <sup>1</sup>Sevilla, ES, <sup>2</sup>Mannheim, DE
- 11:30 - 13:00 Metastatic GIST: Case discussions  
J. Blay<sup>1</sup>, G.D. Demetri<sup>2</sup>, S. George<sup>2</sup>, H. Joensuu<sup>3</sup>, R. Jones<sup>4</sup>, A. Le Cesne<sup>5</sup>, M. Pantaleo<sup>6</sup>, P. Reichardt<sup>7</sup>, J.C. Trent<sup>8</sup>, A. Comandone<sup>9</sup>, G. Grignani<sup>10</sup>, M. Montemurro<sup>11</sup>; <sup>1</sup>Lyon, FR, <sup>2</sup>Boston, MA/US, <sup>3</sup>Helsinki, FI, <sup>4</sup>London, GB, <sup>5</sup>Villejuif, FR, <sup>6</sup>Bologna, IT, <sup>7</sup>Berlin, DE, <sup>8</sup>Houston, TX/US, <sup>9</sup>Torino, IT, <sup>10</sup>Candiolo, (TO)/IT, <sup>11</sup>Lausanne, CH
- 14:00 - 15:00 Multidisciplinary treatment in the localised-disease setting Club bar  
Moderation: X. Garcia del Muro, Barcelona, ES
- 14:00 - 14:30 Adjuvant chemotherapy of STS  
J. Blay, Lyon, FR
- 14:30 - 15:00 Adjuvant therapy of GIST  
H. Joensuu, Helsinki, FI
- 14:00 - 15:30 Localised STS: Case discussions Washington A  
Moderation: K.S. Hall<sup>1</sup>, M. Montemurro<sup>2</sup>; <sup>1</sup>Oslo, NO, <sup>2</sup>Lausanne, CH
- 14:00 - 15:30 Localised STS: Case discussions  
E. Baldini<sup>1</sup>, S. Bonvalot<sup>2</sup>, P.G. Casali<sup>3</sup>, C. Catton<sup>4</sup>, T.F. DeLaney<sup>5</sup>, R.L. Haas<sup>6</sup>, C. Raut<sup>5</sup>, C. Swallow<sup>7</sup>, F. Van Coevorden<sup>6</sup>, C. Le Pechoux<sup>8</sup>, A. De Paoli<sup>9</sup>; <sup>1</sup>Boston, US, <sup>2</sup>Paris, FR, <sup>3</sup>Milan, IT, <sup>4</sup>Toronto, CA, <sup>5</sup>Boston, MA/US, <sup>6</sup>Amsterdam, NL, <sup>7</sup>Toronto, ON/CA, <sup>8</sup>Villejuif, FR, <sup>9</sup>Aviano, Pordenone/IT

15:30 - 18:00 The medical approach in the advanced-disease setting Club bar  
Moderation: A. Comandone<sup>1</sup>, G. Grignani<sup>2</sup>; <sup>1</sup>Torino, IT, <sup>2</sup>Candiolo, (TO)/IT

15:30 - 16:00 Principles of systemic therapy of STS  
B. Kasper, Mannheim, DE

16:00 - 16:30 Histology- and molecularly-driven medical therapy of STS  
R. Jones, London, GB

16:30 - 17:00 Targeted therapy of metastatic GIST  
P. Reichardt, Berlin, DE

17:00 - 17:30 Practical management of TKI treatment in GIST  
A. Le Cesne, Villejuif, FR

17:30 - 18:00 Immune therapy of STS & GIST  
J. Blay, Lyon, FR

16:00 - 17:30 Metastatic STS: Case discussions Washington A  
Moderation: H. Gelderblom<sup>1</sup>, W. van der Graaf<sup>2</sup>; <sup>1</sup>Leiden, NL, <sup>2</sup>Sutton, Surrey/GB

16:00 - 17:30 Metastatic STS: Case discussions  
S. D'Angelo<sup>1</sup>, C. Fletcher<sup>2</sup>, A.M. Frezza<sup>3</sup>, M. Gounder<sup>1</sup>, L. Helman<sup>4</sup>, R. Maki<sup>1</sup>, S. Patel<sup>5</sup>, P. Schoeffski<sup>6</sup>,  
S. Stacchiotti<sup>3</sup>, W.D. Tap<sup>1</sup>, A. Wagner<sup>2</sup>, M. Aglietta<sup>7</sup>, M. D'Incalci<sup>3</sup>, A. Italiano<sup>8</sup>, D. Sangiolo<sup>9</sup>; <sup>1</sup>New  
York, NY/US, <sup>2</sup>Boston, MA/US, <sup>3</sup>Milan, IT, <sup>4</sup>Bethesda, MD/US, <sup>5</sup>Houston, TX/US, <sup>6</sup>Leuven, BE, <sup>7</sup>  
Candiolo, IT, <sup>8</sup>Bordeaux, CEDEX/FR, <sup>9</sup>Candiolo, (TO)/IT

## 06.02.2018

08:00 - 08:30 Opening & Welcome Washington  
Moderation: J. Blay<sup>1</sup>, A..P. Dei Tos<sup>2</sup>, P.G. Casali<sup>3</sup>; <sup>1</sup>Lyon, CEDEX/FR, <sup>2</sup>Treviso, IT, <sup>3</sup>Milan, IT

08:00 - 08:10 Welcome by ESMO  
P.G. Casali, Milan, IT

08:10 - 08:20 Welcome by INT - Milan  
G. Apolone, Milan, IT

08:20 - 08:30 Welcome by SPAEN  
M. Wartenberg, Wölfersheim, Hessen/DE

08:30 - 09:50	State of the art Moderation: A..P. Dei Tos <sup>1</sup> , J. Blay <sup>2</sup> ; <sup>1</sup> Treviso, IT, <sup>2</sup> Lyon, CEDEX/FR	Washington
08:30 - 08:50	Pathology and genetics of STS <u>C. Fletcher</u> , Boston, MA/US	
08:50 - 09:10	The medical treatment of STS <u>S. Patel</u> , Houston, TX/US	
09:10 - 09:30	The GIST genotypes relevant to therapy <u>S. Bauer</u> , Essen, DE	
09:30 - 09:50	The medical treatment of GIST <u>H. Joensuu</u> , Helsinki, FI	
10:20 - 12:30	Surgery Moderation: P. Picci <sup>1</sup> , F. Van Coevorden <sup>2</sup> ; <sup>1</sup> Bologna, IT, <sup>2</sup> Amsterdam, NL	Washington
10:20 - 10:40	Why is the “sarcoma” surgical margin different from the “epithelial”? <u>C. Raut</u> , Boston, MA/US	
10:40 - 11:00	Should we stratify the surgical margin across STS histologies? <u>A. Gronchi</u> , Milan, IT	
11:00 - 11:20	How the surgical margin has changed in retroperitoneal sarcomas? <u>C. Swallow</u> , Toronto, ON/CA	
11:20 - 11:40	When surgery should be done in desmoids? <u>S. Bonvalot</u> , Paris, FR	
11:40 - 12:00	Has surgery of lung metastases in sarcomas evolved from the XIX century on? <u>P. Hohenberger</u> , Mannheim, DE	
12:00 - 12:20	Is the GIST surgical margin different? <u>P. Rutkowski</u> , Warsaw, PL	
12:20 - 12:30	Discussion	
13:30 - 14:30	Industry Satellite Symposium	Washington

14:40 - 16:10	Radiation therapy	Washington
	Moderation: C. Le Pechoux <sup>1</sup> , A. De Paoli <sup>2</sup> ; <sup>1</sup> Villejuif, CEDEX/FR, <sup>2</sup> Aviano, Pordenone/IT	
14:40 - 15:00	Does radiation therapy improve survival in STS? <u>R.L. Haas</u> , Amsterdam, NL	
15:00 - 15:20	Is preoperative radiation therapy better? <u>C. Catton</u> , Toronto, CA	
15:20 - 15:40	Is there a rationale for radiation therapy in retroperitoneal sarcomas? <u>E. Baldini</u> , Boston, US	
15:40 - 16:00	Should we use proton or carbon ion radiation therapy in any STS today? T.F. DeLaney, Boston, MA/US	
16:00 - 16:10	Discussion	
16:40 - 19:00	Chemotherapy	Washington
	Moderation: M. Aglietta <sup>1</sup> , M. D'Incalci <sup>2</sup> ; <sup>1</sup> Candiolo, (TO)/IT, <sup>2</sup> Milan, IT	
16:40 - 17:00	Can we reach a consensus on the value of neoadjuvant & adjuvant chemotherapy in STS? <u>R.S. Benjamin</u> , Houston, TX/US	
17:00 - 17:20	Can the pathologist say if a patient has responded to preoperative chemotherapy? <u>A..P. Dei Tos</u> , Treviso, IT	
17:20 - 17:40	Can we get to an evidence-based histology-driven chemotherapy in advanced STS? <u>P.G. Casali</u> , Milan, IT	
17:40 - 18:00	Are we prolonging survival with chemotherapy in metastatic STS? <u>A. Le Cesne</u> , Villejuif, CEDEX/FR	
18:00 - 18:20	The case of uterine sarcomas <u>S. George</u> , Boston, MA/US	
18:20 - 18:40	The case of histiocytic/dendritic cell neoplasms <u>A.M. Frezza</u> , Milan, IT	
18:40 - 19:00	Discussion	

07.02.2018

08:00 - 10:50	Targeted therapy of GIST & STS Moderation: R. Maestro <sup>1</sup> , A. Italiano <sup>2</sup> ; <sup>1</sup> Aviano, PN/IT, <sup>2</sup> Bordeaux, CEDEX/FR	Washington
08:00 - 08:20	The clinical usefulness of profiling “wild-type” GIST <u>J.C. Trent</u> , Houston, TX/US	
08:20 - 08:40	The clinical management of TKIs in GIST <u>P. Reichardt</u> , Berlin, DE	
08:40 - 09:00	Current and future molecular biology of secondary resistance in GIST <u>J.A. Fletcher</u> , Boston, MA/US	
09:00 - 09:20	Current and future approach to secondary resistance in GIST <u>G.D. Demetri</u> , Boston, MA/US	
09:20 - 09:40	Actually actionable targets in STS <u>P. Schoeffski</u> , Leuven, BE	
09:40 - 10:00	Histology-agnostic NGS for therapy in STS? <u>A. Wagner</u> , Boston, MA/US	
10:00 - 10:20	Can we get to an evidence-based targeted therapy of “rare” STS histologies? <u>S. Stacchiotti</u> , Milan, IT	
10:20 - 10:40	Epigenetics and new avenues in STS <u>M. Gounder</u> , New York, NY/US	
10:40 - 10:50	Discussion	

11:20 - 13:30	Immune therapy Moderation: D. Sangiolo <sup>1</sup> , C. Castelli <sup>2</sup> ; <sup>1</sup> Candiolo, (TO)/IT, <sup>2</sup> Milan, IT	Washington
11:20 - 11:40	Will we get to an evidence-based immune therapy in STS? <u>R. Maki</u> , New York, NY/US	
11:40 - 12:00	Mutational load and immune microenvironment in STS and in the STS patient <u>J. Blay</u> , Lyon, CEDEX/FR	
12:00 - 12:20	Is there a rationale for immune therapy in GIST? <u>R.P. DeMatteo</u> , New York, NY/US	
12:20 - 12:40	Should we combine immune therapy agents with what? <u>S. D'Angelo</u> , New York, NY/US	
12:40 - 13:00	Next-generation immune therapy in STS <u>W.D. Tap</u> , New York, NY/US	
13:00 - 13:20	Will adoptive immune therapy be the way forward in "cold" STS? <u>L. Helman</u> , Bethesda, MD/US	
13:20 - 13:30	Discussion	
14:20 - 15:20	Industry Satellite Symposium	Washington

15:30 - 17:25	Round table with SPAEN Moderation: R. Wilson <sup>1</sup> , P.G. Casali <sup>2</sup> ; <sup>1</sup> London, GB, <sup>2</sup> Milan, IT	Washington
15:30 - 15:45	Does evidence-based medicine discriminate the sarcoma patient? <u>P. Bruzzi</u> , Genova, IT	
15:45 - 16:00	Insights to Sarcoma and GIST in India <u>N. Guhagarkar</u> , Mumbai, IN	
16:00 - 16:15	Can we improve the pathologic diagnosis in STS? <u>A..P. Dei Tos</u> , Treviso, IT	
16:15 - 16:30	Using the Internet to improve trial recruitment – issues for joint action <u>K. Schuster</u> , Wölfersheim, DE	
16:30 - 16:45	Will ERN improve quality of care of STS & GIST in the EU? <u>P.G. Casali</u> , Milan, IT	
16:45 - 17:00	Patient Priorities – Five Challenges <u>R. Wilson</u> , London, GB	
17:00 - 17:25	Discussion	
17:25 - 17:30	Conclusions	Washington
17:25 - 17:30	Take-home message: The value of multidisciplinary in STS & GIST <u>P.G. Casali</u> , Milan, IT	